Jason Efstathiou/X
May 17, 2025, 15:15
Jason Efstathiou: Looking Forward to PTCOG 2025 Next Month
Jason Efstathiou, Professor of Radiation Oncology at Harvard Medical School, posted on X:
“Looking forward to PTCOG next month, where I will be discussing the PARTIQoL trial in a plenary session.
PARTIQoL is a major win for radiation oncology and, most importantly, for patients.
What did the Phase 3 trial comparing proton therapy and IMRT in prostate cancer reveal?
Both approaches provided equally high tumor control rates and no differences in patient-reported quality of life for patients with localized low- and intermediate-risk prostate cancer. Watch the full discussion.”
Further Reading: 63rd Annual PTCOG Conference.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 17, 2025, 15:15
May 17, 2025, 15:04
May 17, 2025, 15:03
May 17, 2025, 14:56
May 17, 2025, 12:46
May 17, 2025, 12:40
May 17, 2025, 12:34